Ketoconazole and fluconazole, another CYP51 inhibitor, have shown promise for the treatment of cutaneous leishmaniasis in clinical trials (Alrajhi et al., 2002; Saenz et al., 1990). This evidence concerns the gene CYP51A1 and cutaneous leishmaniasis.